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co-administration of the peripheral a2-adrenoceptor agonist
vatinoxan (MK-467) with medetomidine and butorphanol
prior to intravenous (IV) ketamine on the cardiopulmonary
and anaesthetic effects in dogs, followed by atipamezole
reversal.
Study design Randomized, masked crossover study.
Animals A total of eight purpose-bred Beagle dogs aged 3
years.
Methods Each dog was instrumented and administered two
treatments 2 weeks apart: medetomidine (20 mg kge1) and
butorphanol (100 mg kge1) premedication with vatinoxan
(500 mg kge1; treatment MVB) or without vatinoxan
(treatment MB) IM 20 minutes before IV ketamine (4 mg
kge1). Atipamezole (100 mg kge1) was administered IM 60
minutes after ketamine. Heart rate (HR), mean arterial
(MAP) and central venous (CVP) pressures and cardiac
output (CO) were measured; cardiac (CI) and systemic
vascular resistance (SVRI) indices were calculated before
and 10 minutes after MVB or MB, and 10, 25, 40, 55, 70
and 100 minutes after ketamine. Data were analysed with
repeated measures analysis of covariance models. A p-value
<0.05 was considered statistically significant. Sedation,
induction, intubation and recovery scores were assessed.
Results At most time points, HR and CI were significantly
higher, and SVRI and CVP significantly lower with MVB
than with MB. With both treatments, SVRI and MAP
decreased after ketamine, whereas HR and CI increased.604hypotension (57e59 mmHg) was recorded in two dogs
with MVB prior to atipamezole administration. Sedation,
induction, intubation and recovery scores were not different
between treatments, but intolerance to the endotracheal
tube was observed earlier with MVB.
Conclusions and clinical relevance Haemodynamic per-
formance was improved by vatinoxan co-administration
with medetomidineebutorphanol, before and after keta-
mine administration. However, vatinoxan was associated
with mild hypotension after ketamine with the dose used in
this study. Vatinoxan shortened the duration of
anaesthesia.
Keywords anaesthesia, butorphanol, cardiopulmonary,
ketamine, medetomidine, vatinoxan.Introduction
a2-Adrenoceptor agonists, such as medetomidine or its phar-
macologically active enantiomer dexmedetomidine, can be
combined with butorphanol resulting in reliable sedation,
muscle relaxation and analgesia for clinical procedures
(Bartram et al. 1994; Ko et al. 2000; Kuo & Keegan 2004;
Lepp€anen et al. 2006). Cardiovascular depression character-
ized by increased systemic vascular resistance index (SVRI)
and decreased heart rate (HR) and cardiac index (CI), attrib-
uted to a2-adrenoceptor agonist-induced peripheral vasocon-
striction and decrease in sympathetic outflow, limit the
usefulness of such combinations (Bartram et al. 1994;
Pypendop & Verstegen 1998; Kuo & Keegan 2004).
Influence of vatinoxan on effects of ketamine H Turunen et al.To reduce these adverse cardiovascular effects in dogs, a
peripheral a2-adrenoceptor antagonist, vatinoxan (also known
as MK-467 and L-659'066) has been tested for concomitant
use with medetomidine. The direct influence of vatinoxan is
restricted to peripheral tissues because of its limited penetration
across the mammalian bloodebrain barrier (Clineschmidt et al.
1988). Therefore, vatinoxan does not markedly counteract
medetomidine-induced sedation (Honkavaara et al. 2008;
Restitutti et al. 2011; Rolfe et al. 2012) but helps to maintain
cardiac output (CO) by preventing the arterial vasoconstrictive
effects of a2-adrenoceptor agonists (Piascik et al. 1996; Pagel
et al. 1998; Enouri et al. 2008; Honkavaara et al. 2011).
Even if the initial haemodynamic effects of medetomidine are
not entirely prevented by intramuscularly (IM) co-
administered vatinoxan, their intensity and duration are
reduced (Restitutti et al. 2017). Similarly, when IM
medetomidineevatinoxan is further combined with butor-
phanol, lesser reductions in HR (Salla et al. 2014; Kallio-Kujala
et al. 2018a) and CI have been observed (Salla et al. 2014).
Ketamine, an antagonist of N-methyl-D-aspartate re-
ceptors, is a dissociative anaesthetic often used for induction
of anaesthesia in dogs. The advantages of premedication with
an a2-adrenoceptor agonist prior to ketamine induction
include a dose-sparing effect and predictable, rapid and
smooth induction of anaesthesia followed by short-lasting
surgical anaesthesia for mildly painful procedures
(Hellebrekers & Sap 1997; Hellebrekers et al. 1998). Post-
procedural recovery may be hastened with the use of an a2-
adrenoceptor antagonist, such as atipamezole (Ko et al.
2000). Anaesthetic doses of ketamine are often associated
with transient respiratory depression that may be intensified
by a2-adrenoceptor agonists and opioids (Ko et al. 2001;
Barletta et al. 2011; Krimins et al. 2012). Ketamine has
sympathomimetic effects, stimulating cardiovascular function
by increasing HR, CO and arterial blood pressure (Haskins
et al. 1985). However, ketamine may also have direct nega-
tive inotropic effects (Pagel et al. 1992).
Ketamine has been investigated for intravenous (IV) anaes-
thetic induction in dogs sedated with medetomidine and vat-
inoxan (Salla et al. 2017), but the dose of ketamine
administered was low (1 mg kge1) and no opioid agent was
used. In the present study, the primary aim was to evaluate the
influence of vatinoxan on cardiopulmonary function and
anaesthetic effects in dogs administered medeto
midineebutorphanol IM 20 minutes before induction of
anaesthesia with a higher IV dose of ketamine (4 mg kge1).
Subsequently, recovery characteristics before and after atipa-
mezole administration were assessed. Atipamezole interacts
favourablywith vatinoxanwhenused to reversemedetomidine-
induced sedation (Turunen et al. 2019). However, there are no
reports of the interaction of atipamezole and vatinoxan with
ketamine.© 2020 Association of Veterinary Anaesthetists and American College of Veterina
open access article under the CC BY-NC-ND license (http://creativecommons.orgWe hypothesized that: 1) vatinoxan would improve cardio-
vascular performance by decreasing SVRI and increasing HR
and CI; 2) by preserving CO, vatinoxan would hasten the
plasma clearance of ketamine and shorten the duration of
anaesthesia; and 3) atipamezole administered 60 minutes after
ketamine would shorten recovery without detrimental adverse
effects. We did not expect any impact of vatinoxan on venti-
lation, clinical quality of induction or intubation between
treatments.
Materials and methods
Animals
A total of eight purpose-bred Beagle dogs (six neutered males
and two neutered females) approximate age 3 years, weighing
13.3 ± 1.7 kg [mean ± standard deviation (SD)] were studied.
The dogs were considered healthy based on history and
comprehensive clinical examinations including complete blood
counts and routine serum chemistry. The dogs were housed in
groups in a kennel, fed with commercial food with free access
to water. Food was withheld for 12 hours prior to experiments.
The study was approved by Finnish Animal Experimental
Board (ESAVI/7187/04.10.03/2012). All dogs have been
rehomed.
Treatments
Each dog was administered two treatments in a randomized
(www.random.org) crossover design, separated by 2 weeks.
Dogs in treatment MVB were premedicated IM with medeto-
midine hydrochloride (20 mg kge1; Dorbene, 1 mg mLe1;
Laboratories SYVA S.A.U., Spain), butorphanol tartrate (100
mg kge1; Torpudor vet, 10 mg mLe1; Richter Pharma AG,
Austria) and vatinoxan hydrochloride (500 mg kge1; Reci-
pharm, Sweden). Dogs in treatment MB were premedicated IM
with medetomidine and butorphanol at the same dose rates.
Drugs were administered from one syringe 20 minutes before
IV ketamine (4 mg kge1; Ketaminol, 50 mg mLe1; Intervet
International B.V., The Netherlands). Atipamezole hydrochlo-
ride (100 mg kge1; Alzane, 5 mg mLe1; Laboratories SYVA
S.A.U.) was administered IM 60 minutes after ketamine.
The medetomidineevatinoxan solution was prepared
immediately before use in a sterile vial containing 25 mg
vatinoxan powder by adding 1 mL medetomidine and 1 mL
physiological saline solution (Natriumklorid, 0.9%; B Braun
Melsungen AG, Germany) and mixing the vial until the solu-
tion was clear by visual inspection. The final drug concentra-
tions in the solution were 500 mg mLe1 of medetomidine and
12.5 mg mLe1 of vatinoxan (ratio, 1:25). The medetomidine
solution was prepared similarly in an empty vial. An injection
volume of 0.04 mL kge1 was drawn from the vial and butor-
phanol was added to the same syringe.ry Anesthesia and Analgesia. Published by Elsevier Ltd. This is an
/licenses/by-nc-nd/4.0/)., 47, 604e613
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Prior to each experiment, each dog was instrumented under
general anaesthesia. A cephalic vein was aseptically cannu-
lated with a 22 gauge catheter for induction of anaesthesia
using propofol (6.3e14.6 mg kge1; Vetofol, 10 mg mLe1;
Norbrook Laboratories, Ireland) administered IV to effect. The
dog was then intubated orotracheally. Anaesthesia was
maintained with isoflurane (Vetflurane 100%; Virbac S. A.,
France) in oxygen delivered via a circle breathing system
(Anesco Inc., FL, USA) maintaining the end-tidal isoflurane
concentration at 1.5%. Mechanical ventilation was applied to
maintain the end-tidal carbon dioxide partial pressure at
35e45 mmHg (4.7e6.0 kPa). Blood pressure, electrocardi-
ography and pulse oximetry were monitored with noninvasive
methods. Acetated Ringer’s solution (Ringer-Acetat Baxter
Viaflo; Baxter Finland, Finland) was infused at 5 mL kge1
houre1. A 20 gauge arterial catheter (Arteriofix V; B Braun
Melsungen AG) was aseptically introduced into a femoral ar-
tery. A 7 Fr double-lumen central venous catheter (CV-12702;
Arrow International Inc., PA, USA) was aseptically inserted
into a jugular vein under local anaesthesia (0.25 mL; Lidocain,
20 mg mL-1; Orion Pharma, Finland), introduced to a pre-
measured distance for the tip of the catheter to reach the
cranial border of the second rib at the costochondral junction
and secured with sutures and a light bandage. Next, delivery of
isoflurane and IV fluid were discontinued, and the dog was
allowed to recover from anaesthesia. At least 60 minutes
elapsed after extubation prior to baseline measurements.
Measurements
The dog was minimally restrained in sternal recumbency on an
examination table covered with an insulating foam pad and
electrical heating pad. The arterial and central venous cathe-
ters were connected to pressure transducers (Gabarith PMSET;
Becton Dickinson Medical, UT, USA) with saline-filled pressure
tubing (Argon Medical Devices Netherlands B.V., Finland). The
accuracy of the transducers was verified before each experi-
ment at values higher and lower than the normal physiological
range using a mercury manometer, and zeroed to atmospheric
pressure at the level of the manubrium. Adhesive electrodes
were placed on the shaved skin of both thoracic limbs and the
left pelvic limb for electrocardiography. Invasive arterial and
venous pressures and a continuous lead II electrocardiogram
(ECG) were monitored (S/5 Anesthesia Monitor; GE Healthcare
Finland Oy, Finland) throughout the session. Immediately after
obtaining baseline values and blood samples, the assigned
treatment was injected into the gluteal muscles of the right
pelvic limb. At 20 minutes after premedication, ketamine was
administered IV over 2 minutes. Orotracheal intubation was
performed immediately after ketamine administration, and
oxygen (1 L minutee1) was delivered via a circle breathing© 2020 Association of Veterinary Anaesthetists and American College
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neous ventilation) occurred, manual ventilation was applied,
peak inspiratory pressure 10e15 cm H2O and 2e3 breaths
minutee1, until spontaneous breathing resumed. Atipamezole
was injected into the gluteal muscles of the left pelvic limb 60
minutes after ketamine. Negative aspiration for blood was
performed to confirm extravascular drug administration for all
IM injections.
The HR (recorded from ECG and confirmed by auscultation
over 1 minute), respiratory rate (fR; counting chest movements
during 1 minute) and blood pressures were recorded first; at
e20 (baseline),e10, 10, 15, 25, 40, 55, 70 and 100 (and 120
for HR) minutes from administration of ketamine. Arterial
blood was anaerobically collected prior to CO measurements
into heparinized syringes (Pico50; Radiometer Medical ApS,
Denmark) and analysed immediately for pH, arterial partial
pressures of carbon dioxide (PaCO2) and oxygen (PaO2),
lactate, sodium and haemoglobin concentrations (ABL 855;
Radiometer Medical ApS), corrected to individual rectal tem-
perature. CO was measured with the lithium dilution method
(LiDCO Plus haemodynamic monitor; LiDCO Ltd, UK) using a
standard dose of 0.075 mM of lithium chloride (LiDCO Ltd)
injected via the central venous catheter (Mason et al. 2001) at
e20 (baseline),e10, 10, 25, 40, 55, 70 and 100minutes from
the administration of ketamine. Initial standard values of 10 g
dLe1 for haemoglobin and 140mmol Le1 for sodium were later
corrected with actual values obtained from arterial blood. CI,
stroke volume index (SVI), rate pressure product (RPP) and
SVRI were calculated using standard equations (Haskins et al.
2005).
Venous blood (6 mL, tubes containing ethyl-
enediaminetetraacetic acid) was collected from the central
venous catheter at 10, 40, 55 and 70 minutes for plasma
concentration analyses of studied drugs (dexmedetomidine,
butorphanol, ketamine, vatinoxan, atipamezole). Samples
were separated by refrigerated centrifugation (2520 g for 15
minutes at 4 C), and plasma was kept frozen at e20 C or
colder until analysed. The purpose of drug concentration
analysis was to detect the influence of vatinoxan on plasma
concentrations of co-administered drugs, and comparison with
clinical observations.
Composite sedation scores (ranging from 0, no sedation, to
20, deep sedation) were determined after recording HR. In-
duction scores (ideal, good, unsatisfactory, not reached), jaw
tone (poor, slight, good, total) and intubation scores (smooth,
mild coughing, pronounced coughing, swallowing or gagging,
failed attempt) were recorded immediately after successful
endotracheal intubation. The early recovery score (easy or
fairly easy transition to alertness, restless, needs restraint) was
assessed after extubation and the late recovery score (alert and
responsive, slightly sedated, sedated, very sedated) 120 mi-
nutes after ketamine administration. An investigator (HT)of Veterinary Anesthesia and Analgesia. Published by Elsevier Ltd. This is an
license (http://creativecommons.org/licenses/by-nc-nd/4.0/)., 47, 604e613
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assigned all scores. Times from administration of premed-
ication to sedation, defined as the head resting on the table,
and to return of consciousness were recorded. The times when
the dog coughed or swallowed around the endotracheal tube,
resulting in extubation and any adverse clinical signs during
recovery, such as nausea, were recorded. After recovery from
anaesthesia, the catheters were removed and meloxicam (0.2
mg kge1; Metacam, 5 mg mLe1; Boehringer Ingelheim Vet-
medica GmbH, Germany) was administered subcutaneously.
The dog was offered food prior to returning to its kennel.
Analytical methods
Concentrations of dexmedetomidine in canine plasma were
determined with chiral high-performance liquid
chromatographyemass spectrometry (HPLCeMS/MS, Sciex
API 4000; AB Sciex Pte. Ltd, ON, Canada) as described pre-
viously (Adam et al. 2018). Reference samples were prepared
in drug-free canine plasma. The precursor ionefragment ion
pairs monitored were m ze1 201.2e95.1 for dexmedetomidine
and m ze1 204.2e98.1 for the internal standard, deuterated
(D3) medetomidine. The accuracy of the quality control sam-
ples (at concentrations of 0.225, 1.0 and 8.0 ng mLe1) ranged
from 91.3% to 99.1%, and intra-assay coefficient of variation
at these concentrations ranged from 1.2% to 3.9% for
dexmedetomidine.
The concentrations of butorphanol, ketamine, atipamezole
and vatinoxan in plasma were analysed with HPLCeMS/MS
(Waters Acquity UPLC þ Waters TQ-S triple quadripole MS;
Waters Corp., MA, USA) (Kallio-Kujala et al. 2018b). The
selected reaction monitoring was m ze1 of 328 > 124 for
butorphanol, m ze1 of 238 > 220 for ketamine, m ze1 of 213 >
117 for atipamezole, m ze1 of 419 > 200 for vatinoxan and m
ze1 of 260 > 116 for the employed internal standard pro-
pranolol. Results of all quality control samples were within
85% to 115% of their nominal concentration.
Statistical methods
The sample size calculations were based on data (mean ± SD)
from previous studies (Honkavaara et al. 2008, 2011;
Restitutti et al. 2017). Differences (peak effects) between
treatments (paired two-tailed test, a-level 0.05, power 80%)
were detected using eight dogs: HR 11 beats minutee1 (50 ±
10 versus 61 ± 10 beats minutee1), CO 1.4 L minutee1 (4.0 ±
1.0 versus 5.4 ± 1.2 L minutee1), mean arterial pressure
(MAP) 17 mmHg (110 ± 10 versus 93 ± 15 mmHg).
Differences in several responses within and between treat-
ments were evaluated with repeated measures analysis of
covariance models. For between-treatment comparisons,
actual values were used as response in the model, and for
within-treatment comparisons change from baseline was used.© 2020 Association of Veterinary Anaesthetists and American College of Veterina
open access article under the CC BY-NC-ND license (http://creativecommons.orgThe models included the main effects of treatment and time
point, two-way interactions of treatment and time point, and a
baseline covariate as fixed effects, and the main effect of dog,
the two-way interactions of dog and time point and dog and
treatment as random effects. Additionally, the values after
ketamine and atipamezole were evaluated including only time
points after administration, and the values prior to ketamine
and atipamezole administration were used as baseline cova-
riates. With continuous variables measured only once,
depending on their distribution, either paired t tests or Wil-
coxon’s signed rank-sum test were used. Differences in the
occurrence of nausea (yes or no) were evaluated with McNe-
mar’s test. Normality assumptions were checked with
KolmogoroveSmirnov test. In case normality assumptions
were not met, common transformations were used (logarithm,
inverse). Estimates of treatment differences were calculated
over time and by time point with contrasts from the fitted
models. Similarly, within-group changes were calculated for
each time point with contrasts from the fitted models. Differ-
ences in plasma drug concentrations and their areas under the
curve (AUCs) were compared with paired, two-tailed t tests.
For the group differences and within-group changes, 95%
confidence intervals and p values were calculated. The p values
by time point were adjusted using the Bonferroni correction
within each model (and treatment) and p values <0.05 were
considered statistically significant. SAS for Windows Version
9.3 (SAS Institute Inc.; NC, USA) was used for all statistical
analyses.
Results
At 10 minutes after IM administration of premedication (MB or
MVB), significant decreases in HR (p < 0.001) and CI (p <
0.004), and significant increases in CVP (p < 0.001) and SVRI
(p < 0.007) from baseline were detected with both treatments
(Fig. 1 & Table 1). Values were significantly lower for HR and
CI, whereas significantly higher for CVP, MAP and SVRI (p <
0.001) with MB than with MVB. After ketamine, HR (p <
0.001) and CI (p < 0.004) increased significantly, and SVRI (p
< 0.001) decreased significantly with both treatments when
compared with values at e10 minutes. MAP was significantly
lower in MVB than in MB after ketamine, and MAP 57e59
mmHg was observed in two dogs 40 and 55 minutes after
ketamine (p < 0.007). SVRI decreased (p < 0.001) and CI
increased (p < 0.005) in both treatments 10 minutes after
atipamezole administration.
In both treatments, fR decreased significantly from baseline
at e10 minutes (Table 2). fR stayed significantly lower than
baseline for 55 minutes after ketamine administration in both
treatments (p < 0.001). In MVB at e10 minutes, PaO2
decreased (range, 69.1e95.9 mmHg; 10.8e13.2 kPa; p ¼
0.046) and PaCO2 increased (37.5e43.6 mmHg; 5.0e5.8ry Anesthesia and Analgesia. Published by Elsevier Ltd. This is an
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Figure 1 Mean ± standard deviation of (a) heart rate, (b) cardiac index, (c) mean arterial pressure and (d) systemic vascular resistance index of
eight dogs administered intramuscular (IM) premedication with medetomidine (20 mg kge1) and butorphanol (100 mg kge1; treatment MB; open
squares) or medetomidine and butorphanol at the same dose rates with vatinoxan (500 mg kge1; treatment MVB; solid circles) 20 minutes before
intravenous ketamine (4 mg kge1; ❶) and 80 minutes before IM atipamezole (100 mg kge1; ❷). *Significant difference between treatments (p <
0.05). ySignificantly different from e20 minutes within the treatment (p < 0.05). zSignificantly different from e10 minutes within the treatment
(p < 0.05). xSignificantly different from 55 minutes within a treatment (p < 0.05).
Influence of vatinoxan on effects of ketamine H Turunen et al.kPa; p ¼ 0.013). Arterial pH and lactate concentration were
significantly lower in MVB than in MB at e10 minutes (p ¼
0.016 and p < 0.001, respectively; Table 2). Ventilation was
assisted for 1e16 minutes to treat apnoea in six of the eight
dogs in both treatments immediately after ketamine adminis-
tration. PaCO2 was higher at 10 minutes than at e10 minutes
in both treatments (p < 0.001), and higher in MB than in MVB
(51.8e70.1 mmHg; 6.9e9.3 kPa versus 48.2e59.2 mmHg;
6.4e7.9 kPa, respectively; p ¼ 0.06).
Composite sedation scores indicated marked sedation after
both premedications. There were no significant differences
between the treatments in induction scores, jaw tone or
intubation scores. Induction score was assessed ideal in all dogs
with both treatments, and the mouth could be opened without
resistance in six dogs in MB and seven dogs in MVB. Mild
coughing, during or immediately after endotracheal intuba-
tion, was recorded in two dogs in MB and three dogs in MVB.
Composite sedation score was lower in MVB than in MB at
55 and 60 minutes after ketamine administration (p < 0.001).© 2020 Association of Veterinary Anaesthetists and American College
open access article under the CC BY-NC-ND
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after ketamine administration in MVB and MB, respectively.
Six dogs in MVB and one dog in MB were extubated before
administration of atipamezole. After atipamezole was admin-
istered at 60 minutes, dogs were alert at 64 ± 11 and 68 ± 4
minutes in MVB and MB, respectively. With MVB, the transi-
tion to alertness was fairly easy in five dogs and easy in two
dogs, but one dog was restless during early recovery. With MB,
transition was easy in seven dogs and fairly easy in one dog.
Late recovery scores at 120 minutes after ketamine adminis-
tration did not differ between treatments; six dogs were alert
and responsive and two dogs were slightly sedated or slow to
react. Nausea, defined as drooling, swallowing or lack of
appetite, was recorded in three dogs in MVB and two dogs in
MB. Defaecation was observed in one dog in MB and tenesmus
with mucous faeces in one dog in MVB.
Plasma concentrations of dexmedetomidine and butor-
phanol were higher at 90 and 30 minutes, respectively, after
premedication in MVB than in MB (Fig. 2). Plasma ketamineof Veterinary Anesthesia and Analgesia. Published by Elsevier Ltd. This is an
license (http://creativecommons.org/licenses/by-nc-nd/4.0/)., 47, 604e613
Table 1 Cardiovascular variables in eight dogs that were administered intramuscularly (IM) medetomidine (20 mg kge1) and butorphanol
(100 mg kge1; treatment MB) or medetomidine (20 mg kge1), vatinoxan (500 mg kge1) and butorphanol (100 mg kge1; treatment MVB)
immediately after baseline measurements at time e20. Intravenous injection of ketamine (4 mg kg-1) was administered at time 0. Intra-
muscular injection of atipamezole (100 mg kg-1) was administered at time 60. Values are mean ± standard deviation
Variable Treatment Time (minutes)
e20 e10 10 15 25 40 55 70 100
SAP
(mmHg)
MB 163 ± 28 185 ± 20z 159 ± 17 152 ± 12z 145 ± 15yz 139 ± 13yz 134 ± 13yz 143 ± 23z 147 ± 15
MVB 164 ± 14 154 ± 14*y 107 ± 16*yz 107 ± 13*yz 106 ± 12*yz 105 ± 11*yz 107 ± 9*yz 148 ±23zx 150 ±16zx
DAP
(mmHg)
MB 80 ± 7 108 ± 5y 106 ± 7y 93 ± 8 78 ± 10z 73 ± 10z 70 ± 8z 75 ± 14z 76 ± 10z
MVB 84 ± 9 91 ± 38* 59 ± 8*yz 54 ± 9*yz 52 ± 10*yz 51 ± 8*yz 49 ± 8*yz 72 ± 14zx 72 ± 11zx
CVP
(mmHg)
MB 1 ± 1 8 ± 1y 5 ± 1y 4 ± 1yz 3 ± 1yz 3 ± 1yz 3 ± 1yz 1 ± 1zx 2 ± 1z
MVB 1 ± 2 4 ± 2*y e1 ± 2*yz e1 ± 2*yz 0 ± 2*z 0 ± 2*z 0 ± 2*z e1 ± 3*yz 0 ± 2*z
SVI
mL kge1
MB 2.0 ± 0.3 1.4 ± 0.2y 1.4 ± 0.5y e 1.8 ± 0.4 1.9 ± 0.3z 1.8 ± 0.6 2.7 ± 0.5yzx 2.1 ± 0.5z
MVB 1.8 ± 0.3 1.8 ± 0.3 1.7 ± 0.4 e 1.6 ± 0.3 2.0 ± 0.3 1.9 ± 0.4 2.0 ± 0.6* 2.2 ± 0.3
RPP
(mmHg
minutee1)
MB 7700 ± 644 4720 ± 877y 9690 ± 1570z 6720 ± 546z 4900 ± 414y 3880 ± 912yz 3440 ± 478yz 5620 ± 1400y 5570 ± 1210y
MVB 8350 ± 1830 4930 ± 629y 7320 ± 1780z 6100 ± 929 5100 ± 964y 4110 ± 905y 3830 ± 947yz 11500 ± 5900*zx 8970 ± 4490*zx
CVP, central venous pressure; DAP, diastolic arterial pressure; RPP, rate pressure product; SAP, systolic arterial pressure; SVI, stroke volume index.
* Significantly different fromMB at the same time (p < 0.05). y Significantly different from timee20 within the same treatment (p < 0.05). z Significantly different from timee10
within the same treatment (p < 0.05). x Significantly different from time 55 within the same treatment (p < 0.05).
Influence of vatinoxan on effects of ketamine H Turunen et al.concentration was higher 10 minutes after IV administra-
tion in MB than in MVB. The AUC of ketamine at 10e70
minutes was significantly smaller in MVB (36,700 ± 5200
minute ng mLe1) than in MB (63,600 ± 14,700 minute ng
mLe1).
Discussion
Overall, vatinoxan attenuated the medetomidine-evoked de-
creases in HR and CI by reducing SVRI but did not completely
prevent the early cardiovascular changes. FullTable 2 Mean ± standard deviation of respiratory rate (fR), arterial pa
concentration and rectal temperature (RT) in eight dogs. Variables wer
premedication (time e10) with medetomidine (20 mg kge1) and butorp
vatinoxan (500 mg kge1) and butorphanol (100 mg kge1; treatment M
administered at time 0 and after IM atipamezole (100 mg kge1) at time
Variable Treatment Time (minutes)
e20 e10 10 2
fR (breaths
minutee1)
MB 24 ± 6 13 ± 3y 12 ± 8y 1
MVB 24 ± 6 13 ± 3y 12 ± 6y 1
PaCO2
(mmHg)
MB 35.3 ± 3.0 35.3 ± 3.6 59.1 ± 6.5yz 4
MVB 36.4 ± 1.4 40.9 ± 2.4*y 54.2 ± 4.0*yz 4
PaCO2
(kPa)
MB 4.7 ± 0.4 4.7 ± 0.5 7.9 ± 0.9yz 6
MVB 4.8 ± 0.2 5.4 ± 0.3*y 7.2 ± 0.5*yz 6
pHa MB 7.38 ± 0.02 7.36 ± 0.03 7.23 ± 0.03yz 7
MVB 7.38 ± 0.02 7.34 ± 0.02*y 7.25 ± 0.03*yz 7
Lactate
(mmol Le1)
MB 0.54 ± 0.42 0.76 ± 0.47y 0.84 ± 0.28yz 0
MVB 0.43 ± 0.19 0.42 ± 0.30* 0.56 ± 0.24z 0
RT (C) MB 37.9 ± 0.5 37.8 ± 0.6 37.9 ± 0.7 3
MVB 37.6 ± 0.2 37.4 ± 0.4 37.0 ± 0.6*y 3
* Significantly different from MB at the same time (p < 0.05); y Significantly different from
within the treatment (p < 0.05); x Significantly different from time 55 within the treatme
© 2020 Association of Veterinary Anaesthetists and American College of Veterina
open access article under the CC BY-NC-ND license (http://creativecommons.orgpharmacokinetic evaluation during the absorption phase of
medetomidine, butorphanol and vatinoxan could not be per-
formed in the present study. However, a probable explanation
in previous studies is that vatinoxan accelerates the absorption
and distribution of concomitantly IM administered drugs by
reducing vasoconstriction systemically and at the injection
site; meanwhile the absorption rate of vatinoxan is slower
(Restitutti et al. 2017; Kallio-Kujala et al. 2018b). Further-
more, the central effects of medetomidine are unaffected by
vatinoxan, resulting in decreased HR and CI.rtial pressure of carbon dioxide (PaCO2), arterial pH (pHa), lactate
e recorded before drug administration (time e20), 10 minutes after
hanol (100 mg kge1; treatment MB) or medetomidine (20 mg kge1),
VB) intramuscularly (IM), after intravenous ketamine (4 mg kge1)
60
5 40 55 70 100
7 ± 4 15 ± 8y 14 ± 5y 21 ± 11 22 ± 8z
3 ± 4y 13 ± 4y 12 ± 4y 26 ± 12*zx 29 ± 16zx
7.6 ± 4.6yz 44.3 ± 4.5yz 42.6 ± 4.2yz 40.7 ± 6.1y 37.5 ± 2.9x
7.1 ± 3.6yz 44.2 ± 3.3y 43.5 ± 1.5y 41.3 ± 2.2y 38.7 ± 3.7x
.3 ± 0.6yz 5.9 ± 0.6yz 5.7 ± 0.6yz 5.4 ± 0.8y 5.0 ± 0.4x
.2 ± 0.5yz 5.9 ± 0.4y 5.8 ± 0.2y 5.5 ± 0.3y 5.2 ± 0.5x
.28 ± 0.03yz 7.31 ± 0.03yz 7.32 ± 0.02yz 7.35 ± 0.03yx 7.37 ± 0.03x
.29 ± 0.04yz 7.31 ± 0.03y 7.32 ± 0.02y 7.35 ± 0.02yx 7.35 ± 0.04yx
.78 ± 0.31y 0.81 ± 0.34yz 0.78 ± 0.34y 0.76 ± 0.37y 0.91 ± 1.03y
.60 ± 0.32z 0.64 ± 0.29z 0.55 ± 0.26*z 0.60 ± 0.28z 1.54 ±1.56yzx
7.6 ± 0.6 37.5 ± 0.8 37.5 ± 0.7 37.4 ± 0.5 37.6 ± 0.3x
6.9 ± 0.5*yz 36.9 ± 0.6*yz 36.9 ± 0.6*yz 37.0 ± 0.5yz 37.6 ± 0.3x
time e20 within the treatment (p < 0.05); z Significantly different from time e10
nt (p < 0.05).
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Figure 2 Mean ± standard deviation plasma concentrations of (a) dexmedetomidine, (b) butorphanol and (c) ketamine in eight dogs administered
intramuscular (IM) premedication with medetomidine (20 mg kge1) and butorphanol (100 mg kge1; treatment MB; open squares) or medetomidine
and butorphanol at the same dose rates with vatinoxan (500 mg kge1; treatment MVB; solid circles) 20 minutes before intravenous ketamine (4
mg kge1; ❶) and 80 minutes before IM atipamezole (100 mg kge1; ❷). *Significant difference between treatments (p < 0.05).
Influence of vatinoxan on effects of ketamine H Turunen et al.In both treatments, SVRI and MAP decreased and CI and HR
increased after ketamine administration. These results are
similar to those of a previous study where ketamine adminis-
tered IV approximately 5 minutes after IV xylazine induced
moderate haemodynamic changes with a decrease in SVR and
increases in both HR and CO (Haskins et al. 1986). In the
present study, the increase in CI was attributed mainly to an
increase in HR because SVI was not increased. The significant
decrease in CVP in MVB may have resulted from decreased
preload by less central shifting of peripheral venous blood or
lower SVRI and higher CI. The present study demonstrated
that once the initial vasoconstrictive effect of medetomidine
waned or was prevented by co-administration of vatinoxan,
ketamine reversed the bradycardia and improved CI. However,
because the ketamine effects were transient, they were prob-
ably superseded by the sympatholytic effects of medetomidine.
Hence, a sustained effect may be achieved by repeated or
continuous ketamine administration.
Bloor et al. (1992) reported that dexmedetomidine decreased
plasma noradrenaline and adrenaline concentrations below
those that impact the cardiovascular system, and that after
administration of atipamezole, noradrenaline and adrenaline© 2020 Association of Veterinary Anaesthetists and American College
open access article under the CC BY-NC-ND
610concentrations returned to baseline. Ketamine has direct car-
diovascular depressant effects that are usually masked by the
ensuing sympathetic stimulation opposing its direct vaso-
dilatory and myocardial depressant effects (Diaz et al. 1976).
The positive inotropic effects of ketamine are indirect and
attributed to increased sympathetic nervous system activity
(White et al. 1982). Medetomidine decreases sympathetic
outflow from the central nervous system with decreased
catecholamine concentrations and may blunt ketamine
inotropic effects. Although plasma catecholamine concentra-
tions were not measured, the results of the current study
indicate that vatinoxan did not antagonize the medetomidine-
induced inhibition of noradrenaline and adrenaline release, an
effect that was presumably reversed by atipamezole. The re-
sults obtained indicate that the central cardiovascular
depressor effects of medetomidine probably contributed to the
decreased HR and CI following initial effects of ketamine.
Overall, MAP remained higher in MB because of increased
SVRI. Hypotension was recorded in two dogs in MVB before
atipamezole administration. Nonetheless, tissue perfusion may
have been better maintained in MVB because CI was signifi-
cantly higher and SVRI lower. No differences in RPP wereof Veterinary Anesthesia and Analgesia. Published by Elsevier Ltd. This is an
license (http://creativecommons.org/licenses/by-nc-nd/4.0/)., 47, 604e613
Influence of vatinoxan on effects of ketamine H Turunen et al.detected between treatments, probably because the differences
in MAP were opposed by those in HR. Medetomidine adminis-
tered alone induces a biphasic blood pressure response with an
initial increase in MAP resulting from peripheral vasoconstric-
tion (Schmeling et al. 1991; Bloor et al. 1992; Flacke et al.
1993). Then MAP decreases via a central sympatholytic effect,
becoming more apparent as vasoconstriction wanes (Schmeling
et al. 1991; Bloor et al. 1992; Flacke et al. 1993). Vatinoxan
ameliorates the early hypertensive effect of a2-adrenoceptor
agonists by blocking vascular a2-adrenoceptors (Pagel et al.
1998), and in the absence of the characteristic a2-adreno-
ceptor agonist-induced vasoconstriction, the late depressor ef-
fects may result in decreased MAP. IV administration of
vatinoxan combined with dexmedetomidine at the same dose
ratio of 1:25 as in the present study resulted in no significant
reductions in MAP in conscious dogs (Honkavaara et al. 2011).
Furthermore, no hypotension developed when vatinoxan was
combined with medetomidine and butorphanol (Salla et al.
2014). Therefore, cardiovascular actions of ketamine probably
influenced the temporal effects in the present study.
Notably, except for endotracheal intubation, the dogs in the
present study were not stimulated. In clinical practice, any
surgical or other procedural stimuli may modify the cardio-
vascular function, and combining drugs with vasodilatory,
sympatholytic, negative inotropic or chronotropic effects may
exacerbate the decrease in MAP when administered with
vatinoxan. A limitation of the current study was that there
were no treatments without ketamine.
In both treatments, fR decreased significantly after premed-
ication. Assisted ventilation was required in 75% of the dogs
after ketamine injection and subsequently PaCO2 increased
significantly in both treatments. Similarly, a previous study
reported apnoea in 50% of the dogs administered medetomi-
dine (10 mg kge1) and ketamine (4 mg kge1) (Ko et al. 2001).
A high dose of ketamine (4 mg kge1) was selected for the
present study to ensure appropriate conditions for tracheal
intubation (Ko et al. 2001) and to induce significant cardio-
vascular effects (Pagel et al. 1992). The dose of ketamine
induced apnoea in some dogs, and the incidence was not
influenced by vatinoxan. When using these premedication
combinations with ketamine, preoxygenation is recommended
and a method to support ventilation should be available.
The quality of anaesthesia induction and conditions for
endotracheal intubation were not different between the pre-
treatments, even though inclusion of vatinoxan decreased the
plasma concentration of ketamine. Ketamine concentrations
were probably decreased in MVB compared with MB because
hepatic blood flow was better maintained. Overall smaller AUC
of ketamine manifested clinically as shorter duration of
anaesthesia in MVB than in MB.
The quality of recovery after atipamezole administration in
the present study was not optimal as some dogs exhibited© 2020 Association of Veterinary Anaesthetists and American College of Veterina
open access article under the CC BY-NC-ND license (http://creativecommons.orgnausea and/or defaecation. Ketamine causes salivation and
defaecation in dogs (Haskins et al. 1985; Jacobson& Hartsfield
1993). Atipamezole induces defaecation in dogs by abolishing
the inhibitory effect of medetomidine on colonic motility
mainly via activation of peripheral a2-adrenoceptors (Maugeri
et al. 1994). Vatinoxan may be expected to increase colonic
smooth muscle tone and restore motility. Vomiting and
defaecation have been reported in dogs recovering from sevo-
flurane anaesthesia and vatinoxan administration (Hector
et al. 2017). It is probable that the nausea and defaecation
observed in approximately 30% of the dogs in the present study
was a consequence of multiple drug interactions.
The gastrointestinal distress may have influenced the car-
diovascular variables after atipamezole administration. By
contrast, the increases in HR and CI were much larger than
those recorded in a previous study (Turunen et al. 2019).
However, the effect may have been exaggerated by the atipa-
mezole dose administered, which should have been adjusted
according to the timing of previously administered medeto-
midine. In the present study, atipamezole was administered at
five times the medetomidine dose based on the labelled dose,
even though 80 minutes had elapsed. A lower dose of atipa-
mezole may have reduced gastrointestinal side effects and
cardiovascular response.
Conclusions
Vatinoxan improved haemodynamic function in dogs when
co-administered with medetomidine and butorphanol as pre-
medication for ketamine anaesthesia. Mild hypotension was
recorded in 25% of the dogs using the medetomidine-to-
vatinoxan dose ratio of 1:25. Vatinoxan did not influence the
clinical quality of anaesthesia induction or intubation, but the
duration of anaesthesia was shorter. Atipamezole hastened the
recovery, but the dose should be adjusted to improve the
quality of recovery.Acknowledgements
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